| Literature DB >> 21159629 |
Robert H Goldstein1, Michaela R Reagan, Kristen Anderson, David L Kaplan, Michael Rosenblatt.
Abstract
American women have a nearly 25% lifetime risk of developing breast cancer, with 20% to 40% of these patients developing life-threatening metastases. More than 70% of patients presenting with metastases have skeletal involvement, which signals progression to an incurable stage. Tumor-stroma cell interactions are only superficially understood, specifically regarding the ability of stromal cells to affect metastasis. In vivo models show that exogenously supplied human bone marrow-derived stem cells (hBMSC) migrate to breast cancer tumors, but no reports have shown endogenous hBMSC migration from the bone to primary tumors. Here, we present a model of in vivo hBMSC migration from a physiologic human bone environment to human breast tumors. Furthermore, hBMSCs alter tumor growth and bone metastasis frequency. These may home to certain breast tumors based on tumor-derived TGF-β1. Moreover, at the primary tumor level, interleukin 17B (IL-17B)/IL-17BR signaling may mediate interactions between hBMSCs and breast cancer cells. ©2010 AACR.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21159629 PMCID: PMC3017423 DOI: 10.1158/0008-5472.CAN-10-1254
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701